CAMP
NASDAQ
US
CAMP4 Therapeutics Corporation - Common Stock
$4.72
▲ +$0.25
(+5.59%)
Vol 870
5
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$318.0M
ROE
-99.7%
Margin
-7.3%
D/E
0.13
Beta
-27.62
52W
$1–$8
Wall Street Consensus
12 analysts · Apr 20265
Strong Buy
5
Buy
2
Hold
0
Sell
0
Strong Sell
83.3%
Buy Rating
Price Chart
Similar Stocks
CHRS
Coherus Oncology Inc
P/E 1.1
$171.6M
TENX
Tenax Therapeutics Inc
$76.1M
TLSI
TriSalus Life Sciences Inc
$348.8M
ELDN
Eledon Pharmaceuticals Inc
$113.4M
IKT
Inhibikase Therapeutics Inc
$248.6M
KROS
Keros Therapeutics Inc
P/E 9.6
$620.3M
VYGR
Voyager Therapeutics Inc
$218.5M
ARCT
Arcturus Therapeutics Holdings Inc
$174.2M
RNA
Atrium Therapeutics Inc
$10.9B
Earnings
Beat rate: 40.0%
Next Report
May 11, 2026
EPS Estimate: $-0.21
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.21 | — | — |
| Dec 2025 | $-0.31 | $-0.86 | $-0.55 |
| Sep 2025 | $-0.49 | $-0.55 | $-0.06 |
| Jun 2025 | $-0.69 | $-0.62 | +$0.07 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $652K | $858K | $1.5M | $795K | $348K |
| Net Income | — | -$13.3M | -$12.4M | -$12.6M | -$15.1M | -$40.3M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -129.4% | -129.0% | -129.0% | -129.0% | -129.0% | -99.7% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -7.3% | -7.3% | -7.3% | -7.3% | -7.3% |
| Gross Margin | — | 35.8% | 35.8% | 35.8% | 35.8% | 35.8% |
| D/E Ratio | 0.21 | 0.22 | 0.22 | 0.22 | 0.22 | 0.13 |
| Current Ratio | 5.60 | 5.59 | 5.59 | 5.59 | 5.59 | 9.83 |
Key Ratios
ROA (TTM)
-76.3%
P/S (TTM)
0.05
P/B
1.7
EPS (TTM)
$-2.44
CF/Share
$0.03
Rev Growth 3Y
-2.9%
52W High
$7.50
52W Low
$1.31
$1.31
52-Week Range
$7.50
Financial Health
Free Cash Flow
$6.3M
Net Debt
-$107.5M
Cash
$109.5M
Total Debt
$2.0M
As of Dec 31, 2025
How does CAMP compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
CAMP valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
0.1
▼
100%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
1.7
▼
32%
below
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
CAMP profitability vs Biotechnology peers
ROE
-99.7%
▼
48%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-7.3%
▲
97%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
35.8%
▼
54%
below
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-76.3%
▼
63%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
CAMP financial health vs Biotechnology peers
D/E ratio
0.1
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
In line
Current ratio
9.8
▲
121%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
-27.6
▼
2947%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
CAMP fundamentals radar
CAMP
Peer median
Industry
CAMP profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CAMP vs peers: key metrics
Latest News
Hillman Solutions Acquires Campbell Chain & Fittings From Apex Tool
Nasdaq · Apr 06
Deutsche Bank Sees Weak March for CPG Stocks, Lowers Campbell’s (CPB)
Yahoo Finance · Apr 05
Ukraine Government Schemed To Funnel War Aid To Biden Campaign
ZeroHedge · Mar 26
Pope Leo XIV Suggests Aerial Bombing Campaigns Should Be 'Banned Forever'
ZeroHedge · Mar 25
UBS Cuts PT on The Campbell’s Company (CPB) to $20 From $24 …
Yahoo Finance · Mar 25